Majken Højrup Wiborg, Rasmus Krøijer, Birgitte Schantz Laursen, Lars Lund
{"title":"治疗对Peyronie病实验模型的影响:范围综述。","authors":"Majken Højrup Wiborg, Rasmus Krøijer, Birgitte Schantz Laursen, Lars Lund","doi":"10.1093/sexmed/qfae088","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Peyronie's disease (PD) is a fibrotic disorder affecting the penile tunica albugínea, with unclear pathophysiology despite centuries of recognition.</p><p><strong>Aim: </strong>This scoping review maps the effects of interventions in basic PD research, synthesizing evidence from in vivo and in vitro studies to guide future investigation.</p><p><strong>Methods: </strong>In October-November 2023, a systematic search was conducted across PubMed, Embase (Ovid), Science of Web, and Scopus, following SRYCLE's guidelines. Relevant studies were screened for data on interventions targeting PD in vivo and in vitro, with no language or time restrictions.</p><p><strong>Outcomes: </strong>Primary outcomes included changes in extracellular matrix (ECM) proteins, myofibroblast activity, and plaque size.</p><p><strong>Results: </strong>Of 683 articles screened, 40 studies were included. Key interventions such as phosphodiesterase inhibitors and stem cell therapies reduced ECM proteins and myofibroblast activity, particularly in early-stage PD models. However, none of the studies adhered to the ARRIVE guidelines, highlighting a gap in reporting standards.</p><p><strong>Clinical translation: </strong>Findings suggest potential benefits of early and multimodal treatment strategies, but further human trials are needed to bridge the gap in clinical practice.</p><p><strong>Strengths and limitations: </strong>This review systematically synthesizes animal and cellular research on PD, highlighting significant preclinical findings. However, the lack of standardized reporting and limited human studies restricts direct clinical applicability.</p><p><strong>Conclusion: </strong>Further research should prioritize adherence to reporting standards, optimize treatment timing, and explore combination therapies to advance PD management.</p>","PeriodicalId":21782,"journal":{"name":"Sexual Medicine","volume":"12 6","pages":"qfae088"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726063/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of therapy in experimental models of Peyronie's disease: a scoping review.\",\"authors\":\"Majken Højrup Wiborg, Rasmus Krøijer, Birgitte Schantz Laursen, Lars Lund\",\"doi\":\"10.1093/sexmed/qfae088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Peyronie's disease (PD) is a fibrotic disorder affecting the penile tunica albugínea, with unclear pathophysiology despite centuries of recognition.</p><p><strong>Aim: </strong>This scoping review maps the effects of interventions in basic PD research, synthesizing evidence from in vivo and in vitro studies to guide future investigation.</p><p><strong>Methods: </strong>In October-November 2023, a systematic search was conducted across PubMed, Embase (Ovid), Science of Web, and Scopus, following SRYCLE's guidelines. Relevant studies were screened for data on interventions targeting PD in vivo and in vitro, with no language or time restrictions.</p><p><strong>Outcomes: </strong>Primary outcomes included changes in extracellular matrix (ECM) proteins, myofibroblast activity, and plaque size.</p><p><strong>Results: </strong>Of 683 articles screened, 40 studies were included. Key interventions such as phosphodiesterase inhibitors and stem cell therapies reduced ECM proteins and myofibroblast activity, particularly in early-stage PD models. However, none of the studies adhered to the ARRIVE guidelines, highlighting a gap in reporting standards.</p><p><strong>Clinical translation: </strong>Findings suggest potential benefits of early and multimodal treatment strategies, but further human trials are needed to bridge the gap in clinical practice.</p><p><strong>Strengths and limitations: </strong>This review systematically synthesizes animal and cellular research on PD, highlighting significant preclinical findings. However, the lack of standardized reporting and limited human studies restricts direct clinical applicability.</p><p><strong>Conclusion: </strong>Further research should prioritize adherence to reporting standards, optimize treatment timing, and explore combination therapies to advance PD management.</p>\",\"PeriodicalId\":21782,\"journal\":{\"name\":\"Sexual Medicine\",\"volume\":\"12 6\",\"pages\":\"qfae088\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726063/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sexual Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/sexmed/qfae088\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sexmed/qfae088","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:佩罗尼氏病(PD)是一种影响阴茎膜的纤维化疾病albugínea,尽管几个世纪以来人们一直认识到其病理生理机制尚不清楚。目的:本文综述了干预措施在帕金森病基础研究中的作用,综合了体内和体外研究的证据,以指导未来的研究。方法:在2023年10 - 11月,系统检索PubMed、Embase (Ovid)、Science of Web和Scopus,遵循SRYCLE指南。在没有语言和时间限制的情况下,筛选针对PD的体内和体外干预措施的相关研究数据。结果:主要结果包括细胞外基质(ECM)蛋白、肌成纤维细胞活性和斑块大小的变化。结果:在筛选的683篇文章中,纳入了40项研究。磷酸二酯酶抑制剂和干细胞治疗等关键干预措施降低了ECM蛋白和肌成纤维细胞活性,特别是在早期PD模型中。然而,没有一项研究遵循了arrival指南,这凸显了报告标准的差距。临床翻译:研究结果表明早期和多模式治疗策略的潜在益处,但需要进一步的人体试验来弥补临床实践中的差距。优势和局限性:本综述系统地综合了PD的动物和细胞研究,突出了重要的临床前发现。然而,缺乏标准化的报告和有限的人体研究限制了直接的临床适用性。结论:进一步的研究应优先遵循报告标准,优化治疗时机,探索联合治疗,以推进帕金森病的治疗。
Effects of therapy in experimental models of Peyronie's disease: a scoping review.
Background: Peyronie's disease (PD) is a fibrotic disorder affecting the penile tunica albugínea, with unclear pathophysiology despite centuries of recognition.
Aim: This scoping review maps the effects of interventions in basic PD research, synthesizing evidence from in vivo and in vitro studies to guide future investigation.
Methods: In October-November 2023, a systematic search was conducted across PubMed, Embase (Ovid), Science of Web, and Scopus, following SRYCLE's guidelines. Relevant studies were screened for data on interventions targeting PD in vivo and in vitro, with no language or time restrictions.
Outcomes: Primary outcomes included changes in extracellular matrix (ECM) proteins, myofibroblast activity, and plaque size.
Results: Of 683 articles screened, 40 studies were included. Key interventions such as phosphodiesterase inhibitors and stem cell therapies reduced ECM proteins and myofibroblast activity, particularly in early-stage PD models. However, none of the studies adhered to the ARRIVE guidelines, highlighting a gap in reporting standards.
Clinical translation: Findings suggest potential benefits of early and multimodal treatment strategies, but further human trials are needed to bridge the gap in clinical practice.
Strengths and limitations: This review systematically synthesizes animal and cellular research on PD, highlighting significant preclinical findings. However, the lack of standardized reporting and limited human studies restricts direct clinical applicability.
Conclusion: Further research should prioritize adherence to reporting standards, optimize treatment timing, and explore combination therapies to advance PD management.
期刊介绍:
Sexual Medicine is an official publication of the International Society for Sexual Medicine, and serves the field as the peer-reviewed, open access journal for rapid dissemination of multidisciplinary clinical and basic research in all areas of global sexual medicine, and particularly acts as a venue for topics of regional or sub-specialty interest. The journal is focused on issues in clinical medicine and epidemiology but also publishes basic science papers with particular relevance to specific populations. Sexual Medicine offers clinicians and researchers a rapid route to publication and the opportunity to publish in a broadly distributed and highly visible global forum. The journal publishes high quality articles from all over the world and actively seeks submissions from countries with expanding sexual medicine communities. Sexual Medicine relies on the same expert panel of editors and reviewers as The Journal of Sexual Medicine and Sexual Medicine Reviews.